This High-Flying Growth Stock Is Hiding in Plain Sight

There's a maturation banal that has skyrocketed much than Google genitor Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) and Nvidia (NASDAQ: NVDA) implicit the past 12 months. Wall Street loves this stock, with the statement terms people reflecting a imaginable upside of astir 40%.

But I fishy you've ne'er heard of it. Based connected its mean trading measurement of nether 770,000 shares per day, galore investors aren't acquainted with it.

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now, erstwhile you articulation Stock Advisor. See the stocks »

What is this high-flying maturation banal that's seemingly hiding successful plain sight? Rhythm Pharmaceuticals (NASDAQ: RYTM).

One crushed wherefore Rhythm Pharmaceuticals is flying nether the radar for galore investors is its size. The biotech stock's marketplace headdress is lone $6.8 billion. At the opening of 2025, Rhythm was adjacent smaller.

Another origin down Rhythm's comparative anonymity with investors is that it doesn't people high-profile indications that impact millions of people. Instead, the institution focuses connected processing therapies that dainty uncommon familial obesity disorders.

Rhythm's lone approved cause is Imcivree. The therapy is simply a first-in-class melanocortin-4 receptor (MC4R) agonist that treats obesity owed to POMC, PCSK1, oregon LEPR deficiency and Bardet-Biedl syndrome, an ultra-rare familial obesity disease. Sales for Imcivree soared astir 50% twelvemonth implicit twelvemonth successful 2025 to $194 million, based connected Rhythm's preliminary, unaudited figures.

However, the drugmaker whitethorn not stay a one-trick pony for excessively overmuch longer. Rhythm expects to beforehand its oral MC4R agonist bivamelagon into Phase 3 objective investigating successful 2026. Its pipeline besides includes different experimental MC4R agonist, RM-718, successful Phase 1 testing.

Competition isn't a large interest for Rhythm. The lone rival successful the representation is Palatin Technologies (NYSEMKT: PTN), a nanocap biotech institution that's besides processing MC4R agonists. However, Palatin's superior pipeline candidate, PL7737, advances to Phase 1 objective investigating successful the archetypal fractional of 2026. Rhythm has a immense headstart implicit this imaginable competitor.

Wall Street is bullish astir Rhythm Pharmaceuticals successful ample portion due to the fact that the institution has aggregate upcoming catalysts. The astir important is an anticipated support of Imcivree successful treating acquired hypothalamic obesity (HO). The U.S. Food and Drug Administration (FDA) acceptable a PDUFA day of March 20, 2026, for this decision.

Acquired HO affects an estimated 10,000 patients successful the U.S. In addition, different 10,000 patients successful Europe and up to 8,000 patients successful Japan person the disease. While those numbers whitethorn not dependable overly impressive, they correspond a full that's astatine slightest 3.7 times higher than the combined diligent colonisation for Imcivree's existent approved indications.